STML Key Stats
- Stemline Therapeutics to Present at the 26th Annual ROTH Conference noodls 03/06 08:34 ET
- Stemline Therapeutics to Present at Cowen and Company Health Care Conference noodls 02/26 10:07 ET
- Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% Yahoo 02/24 05:48 ET
- Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape Zacks 02/24 03:25 ET
- Stemline Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences noodls 02/20 08:41 ET
- Stemline Therapeutics (STML) Soars: Stock Up 17.5% - Tale of the Tape Zacks 02/12 02:51 ET
- Stemline Therapeutics (STML) Soars: Stock Up 17.5% Yahoo 02/12 01:56 ET
- Ram Selvaraju: A Pair Of Companies Ride The Sea Change In Cancer Therapeutics Seeking Alpha 02/07 14:22 ET
- Stemline Therapeutics to Present at the Leerink Global Healthcare Conference noodls 02/06 07:24 ET
- Stemline Therapeutics (STML) Files $150M Mixed Shelf Street Insider 02/04 08:20 ET
STML Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Stemline Therapeutics Inc is up 116.6% over the last year vs S&P 500 Total Return up 24.21%, Actelion up 102.5%, and Emergent BioSolutions up 83.97%.
Balance Sheet View Statement
Pro Ratings for STML
Pro Strategies Featuring STML
Did Stemline Therapeutics Inc make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: New York
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.